BioInsights - Vol 7 Issue 11

CELL & GENE THERAPY INSIGHTS

November 2021 Issue

Vol 7 Issue 11

Download PDF

Featuring

Issue Spotlight: Cell therapy bioprocessing and automation
Focus: Downstream Bioprocessing
Other articles
Webinar

SPOTLIGHT

Cell therapy bioprocessing and automation

Expert Insight

Considerations for the development of autologous CAR-T cell products

Considerations for the development of autologous CAR-T cell products

A Davidson, G Toledo, K Lilova et al.
11 January 2022
Read
Manufacturing of hematopoietic stem cell gene therapies: opportunities for process automation

Manufacturing of hematopoietic stem cell gene therapies: opportunities for process automation

Carlotta Peticone, Emma Chan
20 December 2021
Read

Innovator Insight

Putting the patient first: new modalities of manufacturing for cell therapy though real-time process changes

Putting the patient first: new modalities of manufacturing for cell therapy though real-time process changes

B Wang, K Wang, C White
10 March 2022
Read
Enabling clinical grade manufacturing of gene-engineered NK cells

Enabling clinical grade manufacturing of gene-engineered NK cells

N Möker, R Romee, E Ullrich
5 January 2022
Read
Improving allogeneic manufacturing workflows

Improving allogeneic manufacturing workflows

Dr. Evan Zynda, Dr. Aditi Singh
4 November 2021
Read

Interview

Lessons for advanced therapy manufacturing flexibility and productivity

Lessons for advanced therapy manufacturing flexibility and productivity

James Miskin PhD
14 December 2021
Read
Critical success factors for tomorrow’s cellular immunotherapies

Critical success factors for tomorrow’s cellular immunotherapies

Bernd Schmidt
13 December 2021
Read

Expert Roundtable

A ddPCR primer: advantages, challenges, and key considerations when adopting Droplet Digital PCR for viral vector manufacture

A ddPCR primer: advantages, challenges, and key considerations when adopting Droplet Digital PCR for viral vector manufacture

L Drouin, F Dorange, B Silvey et al.
13 December 2021
Read

FastFacts

4D-Nucleofector<sup>®️</sup> LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

4D-Nucleofector®️ LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

Timo Gleissner, Andrea Toell
13 December 2021
Read
Making billions (of cells) with adherent cell cultures

Making billions (of cells) with adherent cell cultures

Catherine Siler
6 December 2021
Read

Viewpoint

Driving CARs on the biomanufacturing road to clinical success

Driving CARs on the biomanufacturing road to clinical success

Chelsia Qiuxia Wang, Andy Hee-Meng Tan
10 January 2022
Read
Translation and automation hurdles for cell therapies

Translation and automation hurdles for cell therapies

Jenny A Prange, Beatrix Rauch-Schmid
9 December 2021
Read

Vectors FOCUS

Downstream Bioprocessing

FastFacts

Development of a scalable adeno-associated virus purification process for gene therapy

Development of a scalable adeno-associated virus purification process for gene therapy

Åsa Hagner McWhirter
25 November 2021
Read

Poster

COVID-19 vaccine approvals: key lessons for mRNA therapeutics

COVID-19 vaccine approvals: key lessons for mRNA therapeutics

V PhD, J Barberio, S Zobbi et al.
6 December 2021
Read

Viewpoint

Titration for research grade rAAV: understanding challenges and minimum requirements

Titration for research grade rAAV: understanding challenges and minimum requirements

Javier F Alcudia
6 December 2021
Read

Interview

Stepping foot into a successful partnership to support your viral vector therapy through commercialization

Stepping foot into a successful partnership to support your viral vector therapy through commercialization

Minh Hong, Marc Gaal
12 January 2022
Read
Current trends in AAV downstream bioprocessing and future considerations

Current trends in AAV downstream bioprocessing and future considerations

Michael Mercaldi
6 December 2021
Read
The route to downstream process and analytical innovation for efficient AAV vector manufacture

The route to downstream process and analytical innovation for efficient AAV vector manufacture

Matthew Roach
6 December 2021
Read

Innovator Insight

Enrichment of full rAAV capsids in a scalable, reproducible viral vector manufacturing platform

Enrichment of full rAAV capsids in a scalable, reproducible viral vector manufacturing platform

A Hejmowski, M Olson, A MacIntyre et al.
13 December 2021
Read

Journal articles

Editorial

Adherent versus suspension based platforms: what is the near future of viral vector manufacturing?

Adherent versus suspension based platforms: what is the near future of viral vector manufacturing?

Ramin Baghirzade
9 November 2021
Read

Expert Insight

No cell left behind: engineering gene therapies for cross correction

No cell left behind: engineering gene therapies for cross correction

Jill M Weimer, Jon J Brudvig
7 December 2021
Read

Innovator Insight

Optimizing downstream purification of high-quality plasmid DNA for gene therapy and vaccine production

Optimizing downstream purification of high-quality plasmid DNA for gene therapy and vaccine production

Alejandro Becerra, Johannes F Buyel
2 November 2021
Read

Interview

Combating QC challenges and special needs of cell and gene therapy production

Combating QC challenges and special needs of cell and gene therapy production

Félix Montero-Julian, Rey Mali
23 November 2021
Read
Finding a happy medium: meeting the rising demand for bioproduction media

Finding a happy medium: meeting the rising demand for bioproduction media

Marlin Frechette
14 December 2021
Read
Engineering approaches to adopt automation in tissue engineered and cell therapy product manufacture

Engineering approaches to adopt automation in tissue engineered and cell therapy product manufacture

Ioannis Papantoniou
20 December 2021
Read

FastFacts

Automate and close your cell therapy process with a flexible system: Sepax™ C-Pro capabilities

Automate and close your cell therapy process with a flexible system: Sepax™ C-Pro capabilities

Sonia Bulsara
23 November 2021
Read
How choosing the right transfection reagent can drastically bring down costs of AAV manufacturing

How choosing the right transfection reagent can drastically bring down costs of AAV manufacturing

Maxime Dumont
23 November 2021
Read
mRNA manufacturing platform using CIMmultus® and CIMac® technology for high recovery of stable mRNA drug substance with rapid HPLC analytics

mRNA manufacturing platform using CIMmultus® and CIMac® technology for high recovery of stable mRNA drug substance with rapid HPLC analytics

Rok Sekirnik, Tomas Kostelec
2 December 2021
Read

Poster

mRNA: what is the best purification method?

mRNA: what is the best purification method?

Kelly Flook
2 December 2021
Read

Webinars